Byetta Cancer: What You Should Know When Considering a Byetta Lawsuit

The threat of pancreatic or thyroid cancer is frightening; the reality devastating. If you are considering a Byetta lawsuit, the following information can help:

About Byetta

Byetta (exenatide synthetic) is a GLP-1 receptor agonist, and became FDA-approved on April 28, 2005 for use in adults with Type II Diabetes. Byetta is manufactured by Amylin Pharmaceuticals Inc, and was until recently marketed jointly by Amylin and Eli Lilly, & Co.

The Food & Drug Administration (FDA) approved Byetta to help type-II diabetics better control their blood sugar levels when other medications proved to be insufficient. The twice-daily injection encourages insulin production.

Byetta, which is an injectable drug, is a somewhat new way of treating diabetes, with potential advantages over older medications. Doctors have had success in prescribing Byetta, so much so that in 2010 alone, the diabetes drug was prescribed well over a million times and netted over $550 million in sales for the pharmaceutical giants involved.

Byetta, Pancreatic Cancer, and Thyroid Cancer

At least two studies have shown that Byetta side effects can include pancreatitis, which can and often does lead to the development of pancreatic cancer. Pancreatic cancer is responsible for 6% of all cancer-related deaths.

By 2008, the FDA had received more than 30 reports of acute pancreatitis in Byetta users. Armed with this information, the FDA directed Amylin to conduct six post-marketing studies regarding acute pancreatitis associated with the use of Byetta, as well as to look at the risk of Byetta cancer, including thyroid cancer and pancreatic cancer. Additionally, the FDA has expressed concern that all extended-release diabetes drugs belonging to Byetta’s family of GLP-1 receptor agonists may be linked to thyroid tumors based on tests conducted on rats and monkeys.

While diabetics are more vulnerable to developing pancreatitis than those without the disease, it does appear that taking Byetta can potentially increase that risk. And, if pancreatitis becomes chronic, the inflammation of the pancreas will alter its normal structure and functions.

Our defective drug lawyers believe that Amylin Pharmaceuticals and Eli Lilly & Co. have failed to adequately warn medical practitioners and pharmaceutical consumers about the risk of serious and potentially fatal side effects including pancreatic cancer and thyroid cancer associated with the use of Byetta. If you or someone you know has taken Byetta and developed one of these conditions, you should speak with a defective drug lawyer to learn more about your legal rights. Our lawyers have always handled pharmaceutical injury cases nationally. We are not new to this area of practice. You need a firm with experience to handle a serious injury or death case like a Byetta lawsuit.

Mikal C. Watts is one of the most successful pharmaceutical lawyers in the country. He has handled pharmaceutical and medical device cases, including but not limited to Ortho-Evra, Vioxx, Fen Phen, Rezulin, Zyprexa and Sulzer hip implants. Mr. Watts maintains a 50,000 square foot office building with a staff of over 60 employees devoted to the handling of cases like yours. Let our firm, Watts Guerra LLP, help you and your family.

Disclaimer: The images on this page of the Byetta packaging, product, and/or logo are for informational purposes; this website is neither affiliated with nor sponsored, endorsed, or approved by Amylin Pharmaceuticals Inc.

Free Case Evaluation

Disclaimer | Privacy Policy

Bookmark and Share

Mikal C. Watts

Mikal C. Watts Mikal C. Watts is one of the most successful pharmaceutical lawyers in the country. He has handled many mass torts, including Ortho-Evra, Vioxx, Fen Phen, Rezulin, Zyprexa, and Sulzer hip implants. Mr. Watts leads a team of successful trial lawyers who handle pharmaceutical product liability cases across the country.

Ryan L. Thompson

Ryan L. Thompson Ryan L. Thompson leads the firm's pharmaceutical and medical device litigation department. He serves as the firm's lead counsel for Actos, NuvaRing, DePuy Hips, Transvaginal Mesh, and other torts. Additionally, Ryan was appointed to serve as Co-Lead counsel nationally in the Incretin-Based Therapies MDL by US District Judge Anthony Battaglia for plaintiff's claiming injuries related to Byetta, Januvia, Janumet, and Victoza.
Contact us using our online form, or call us toll-free at 1(800)796-9605.